Company Overview and News

92
The BAK Portfolio: Canadian Weed Is Legal And The Green Rush Has Begun

2018-07-17 seekingalpha
An escalating trade war and a tepid rebound in Canadian cannabis stocks left the portfolio running in the red for the second quarter in a row.
LXX TAP GRWG TWMJF KHRNF MICWF WEED RTI APHQF CGC LXRP

2
LXRP / Lexaria Bioscience Corp. FORM 10-Q (Quarterly Report)

2018-07-13 sec.gov
Lexaria Bioscience Corp.: Form 10-Q - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2018
LXRP

2
LXRP / Lexaria Bioscience Corp. FORM 8-K (Current Report)

2018-07-05 sec.gov
Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 3, 2018 LEXARIA
LXRP

2
LXRP / Lexaria Bioscience Corp. FORM 8-K (Current Report)

2018-07-03 sec.gov
Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 29, 2018 LEXARI
LXRP

2
Lexaria Announces 2018 AGM Results and Corporate Update

2018-07-03 accesswire
KELOWNA, BC / ACCESSWIRE / July 3, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2018 Annual General and Special Meeting. All motions were passed.
LXX LXRP

5
Lexaria Files New Patent Application for Enhancement of Delivery of Lipophilic Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders

2018-06-29 accesswire
KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / June 29, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has filed an important new patent application with the United States Patent and Trademark Office ("USPTO") for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer's, Huntington's, Parkinson's, neuropathic pain and more.
LXX LXRP

30
Canadian Legalization: What's Next For Cannabis Stocks?

2018-06-21 seekingalpha
On June 19, 2018, the Canadian Senate passed The Cannabis Act 52 to 29. The rest of the approval process will be completed before the end of the week.
SNNVF KHRNF ACBFF RTI DTK CGC GSK LXX TWMJF ACB WEED RDDTF OGRMF OGI LXRP

5
LXRP / Lexaria Bioscience Corp. FORM 8-K (Current Report)

2018-06-20 sec.gov
Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 19, 2018 LEXARI
LXRP

3
LXRP / Lexaria Bioscience Corp. FORM 8-K (Current Report)

2018-06-04 sec.gov
Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2018 LEXARIA
LXRP

3
LXRP / Lexaria Bioscience Corp. null

2018-05-31 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0U(# @;V)J#3P\+TQI;F5A
LXRP

5
Lexaria Bioscience Corp. Structures Nicotine & Pharmaceutical Subsidiaries

2018-05-31 accesswire
KELOWNA, BC / ACCESSWIRE / May 31, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that, subject to ongoing legal and tax analysis, it intends to create two wholly-owned subsidiaries that will respectively hold the intellectual property (''IP'') related to, in the case of the first subsidiary, the improved processing and combustion-free delivery of nicotine and nicotine analogs and, in the case of the second subsidiary, delivery of non-steroidal anti-inflammatory drugs (''NSAIDs''), phosphodiesterase (''PDE5'') inhibitors and other active pharmaceutical ingredients.
LXX LXRP

5
Lexaria Announces Exercises of Existing Warrants, Enters Consulting Agreement

2018-05-28 accesswire
KELOWNA, B.C. / ACCESSWIRE / May 28, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces warrant transactions.
LXX LXRP

4
LXRP / Lexaria Bioscience Corp. FORM 8-K (Current Report)

2018-05-27 sec.gov
Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2018 LEXARIA
LXRP

5
Lexaria Bioscience Corp. Receives New Granted Patents

2018-05-23 accesswire
KELOWNA, BC / ACCESSWIRE / May 23, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received notifications that it has received two new US patents granted and additionally expects three new Australian patents granted on or before August 17th.
LXX LXRP

176
30 Marijuana Stocks to Buy as the Future Turns Green

2018-05-14 investorplace
When it comes to cannabis, we’ve come a long way since former President Bill Clinton denied ever inhaling. With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible.
IGCIW MNTR IGC ACBFF DTK HEMP TRTCD CANN LXX CVSI CBIS SRNA LDSYF MJNA APH AMMJ ACAN ABBV SMG LXRP INQD MDCL MSC.H CARA RMHB IIPR.PRA POTN ACB IIPR IMLFF KAYS PKPH TRTC GRNH ABBV APHQF

LXRP: Lexaria Bioscience Corporation (CNSX:LXX) Analysis and Research Report

2017-11-30 - Asif

The company's business plan is currently focused on the development of strategic partnerships with licensees for its patented technology in exchange for up front and/or staged licensing fees over time. Secondarily and more generally, the company continue to investigate national and international opportunities for development and distribution of the Company’s enhanced functional food and supplement product offerings; to investigate expansions and additions to its intellectual property portfolio; and, to search for additional opportunities in alternative health sectors. This includes the acquisition or development of intellectual property if and when the company believe it advisable to do so. The company announced issuance of its first patent by the U.S. Patent and Trademark Office (USPTO) on October 26, 2016 and have received a Notice of Acceptance from the Australian Patent Office with related patent issuance date June 15 2017 No. 2015274698. The company announced on November 2, 2017 a...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 52886N307